The commission plans to bar Bio-Rad from importing certain single-cell products, potentially including the ddSeq Single-Cell Isolator and ddSeq cartridges.
10x Genomics sued Harvard University and 1CellBio, a competing single-cell technology firm, in 2018 over licenses for patents granted to both companies.
The partners will combine the capabilities of S2's Singulator instrument for solid tissue preparation and Dolomite Bio's Nadia single-cell sample prep platform.
A regional court said certain 10x Genomics' products, including older GEM chips and some Chromium instruments, infringed a "utility model," similar to a patent.
The tubes and collection kits meet the requirements of the European In-Vitro Diagnostic Devices Directive, and the company can now commercialize the devices throughout Europe.
Fluidigm logged $26.4 million in revenues compared to $29.0 million a year ago and well short of analysts' consensus estimate of $28.7 million.
Akadeum is currently developing a tool that involves microbubbles to deplete background molecules from circulating tumor cells in liquid biopsies.
The firm will use the net proceeds for research and development, marketing, and general corporate purposes to help commercialize its LX Analyzer technology.
The firm will use the funding to build a high-throughput flow cytometry system that sorts cells based on high-content 3D features.
The lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.